1-[2-(4-Methylphenoxy)ethyl]-2-(2-phenoxyethylsulfanyl)benzimidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[2-(4-Methylphenoxy)ethyl]-2-(2-phenoxyethylsulfanyl)benzimidazole
• 化学式: C₂₄H₂₄N₂O₂S
• 分子量: 404.5
• InChiKey: PNCBJXVNIRRHJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  61.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] INHIBITORS OF ESTROGEN RECEPTOR ALPHA AND THEIR USE AS THERAPEUTICS FOR CANCER<br/>[FR] INHIBITEURS DU RÉCEPTEUR D'ŒSTROGÈNE ALPHA ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES POUR LE CANCER
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2016165007A1

  公开（公告）日：2016-10-20

  This invention provides of compounds having structures of Formula A, uses of these compounds for treatment of various indications, including breast cancer, as well as methods of treatment involving these compounds.

  该发明提供了具有A式结构的化合物，这些化合物的用途包括治疗各种症状，包括乳腺癌等，以及涉及这些化合物的治疗方法。
• Sunscreen Compositions
  申请人：Curie Co. Inc.

  公开号：US20220160601A1

  公开（公告）日：2022-05-26

  Sunscreen compositions and sunscreen active ingredients are disclosed herein which comprise at least one ketone-containing UV filter and at least one primary or secondary amine wherein at least one ketone-containing UV filter and at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter wherein the imine analog has at least one property selected from the group consisting of a) is capable of extending UV protection into a visible region equal to or greater than 400 nm, b) is water resistant, and/or c) prevents or decreases skin penetration. This imine analog may be further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and/or a lysyl oxidase to bind the sunscreen composition or sunscreen active ingredient to a target of interest. Also disclosed are cosmetic or pharmaceutical preparations comprising any of the sunscreen compositions or sunscreen ingredients along with a cosmetically or pharmaceutically acceptable carrier.
• METHODS AND FORMULATIONS FOR TREATMENT OF SPINOBULBAR MUSCULAR ATROPHY
  申请人：ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.

  公开号：US20220226289A1

  公开（公告）日：2022-07-21

  Methods and formulations are provided for treating spinobulbar muscular atrophy in a subject in need thereof. By administering a therapeutically effective amount of a selective androgen receptor modulator or a small molecule such as 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole or a derivative, prodrug, or pharmaceutically acceptable salt thereof, one or more symptoms of spinobulbar muscular atrophy can be ameliorated. The effective amount can be effective to prevent or delay loss of body weight, a loss of mobility, and/or a loss of physical strength in the subject; to prevent or delay neurogenic atrophy and/or to prevent a loss of spinal cord motor neurons in the subject; to restore the frequency of type I myofibers to normal levels for a healthy subject; and/or to reverse testicular atrophy in the subject.
• [EN] METHODS AND FORMULATIONS FOR TREATMENT OF SPINOBULBAR MUSCULAR ATROPHY<br/>[FR] PROCÉDÉS ET FORMULATIONS POUR LE TRAITEMENT DE L'ATROPHIE MUSCULAIRE SPINOBULBAIRE
  申请人：ST JUDE CHILDRENS RES HOSPITAL INC

  公开号：WO2019084365A1

  公开（公告）日：2019-05-02

  Methods and formulations are provided for treating spinobulbar muscular atrophy in a subject in need thereof. By administering a therapeutically effective amount of a selective androgen receptor modulator or a small molecule such as 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole or a derivative, prodrug, or pharmaceutically acceptable salt thereof, one or more symptoms of spinobulbar muscular atrophy can be ameliorated. The effective amount can be effective to prevent or delay loss of body weight, a loss of mobility, and/or a loss of physical strength in the subject; to prevent or delay neurogenic atrophy and/or to prevent a loss of spinal cord motor neurons in the subject; to restore the frequency of type I myofibers to normal levels for a healthy subject; and/or to reverse testicular atrophy in the subject.